Association of ≥ 12 months of delayed surgical treatment for cervical myelopathy with worsened postoperative outcomes: a multicenter analysis of the Quality Outcomes Database.

cervical myelopathy cervical spondylosis clinical scores functional outcomes fusion multicenter registry pain surgical decompression symptom duration weakness

Journal

Journal of neurosurgery. Spine
ISSN: 1547-5646
Titre abrégé: J Neurosurg Spine
Pays: United States
ID NLM: 101223545

Informations de publication

Date de publication:
01 04 2022
Historique:
received: 24 04 2021
accepted: 19 07 2021
pubmed: 6 11 2021
medline: 6 4 2022
entrez: 5 11 2021
Statut: epublish

Résumé

Degenerative cervical myelopathy (DCM) results in significant morbidity. The duration of symptoms prior to surgical intervention may be associated with postoperative surgical outcomes and functional recovery. The authors' objective was to investigate whether delayed surgical treatment for DCM is associated with worsened postoperative outcomes. Data from 1036 patients across 14 surgical centers in the Quality Outcomes Database were analyzed. Baseline demographic characteristics and findings of preoperative and postoperative symptom evaluations, including duration of symptoms, were assessed. Postoperative functional outcomes were measured using the Neck Disability Index (NDI) and modified Japanese Orthopaedic Association (mJOA) scale. Symptom duration was classified as either less than 12 months or 12 months or greater. Univariable and multivariable regression were used to evaluate for the associations between symptom duration and postoperative outcomes. In this study, 513 patients (49.5%) presented with symptom duration < 12 months, and 523 (50.5%) had symptoms for 12 months or longer. Patients with longer symptom duration had higher BMI and higher prevalence of anxiety and diabetes (all p < 0.05). Symptom duration ≥ 12 months was associated with higher average baseline NDI score (41 vs 36, p < 0.01). However, improvements in NDI scores from baseline were not significantly different between groups at 3 months (p = 0.77) or 12 months (p = 0.51). Likewise, the authors found no significant differences between groups in changes in mJOA scores from baseline to 3 months or 12 months (both p > 0.05). Surgical intervention resulted in improved mJOA and NDI scores at 3 months, and this improvement was sustained in both patients with short and longer initial symptom duration. Patients with DCM can still undergo successful surgical management despite delayed presentation.

Identifiants

pubmed: 34740180
doi: 10.3171/2021.7.SPINE21590
doi:

Types de publication

Journal Article Multicenter Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

568-574

Auteurs

David T Asuzu (DT)

1Department of Neurosurgery, University of Virginia, Charlottesville, Virginia.
2Surgical Neurology Branch, National Institute of Neurologic Disorders and Stroke, National Institutes of Health, Bethesda, Maryland.

Jonathan J Yun (JJ)

1Department of Neurosurgery, University of Virginia, Charlottesville, Virginia.

Mohammed Ali Alvi (MA)

3Department of Neurosurgery, Mayo Clinic, Rochester, Minnesota.

Andrew K Chan (AK)

5Department of Neurosurgery, University of California, San Francisco, San Francisco, California.

Cheerag D Upadhyaya (CD)

6Saint Luke's Neurological and Spine Surgery, Kansas City, Missouri.

Domagoj Coric (D)

7Carolina Neurosurgery and Spine Associates, Charlotte, North Carolina.

Eric A Potts (EA)

8Goodman Campbell Brain and Spine, Carmel, Indiana.

Erica F Bisson (EF)

4Department of Neurosurgery, University of Utah, Salt Lake City, Utah.

Jay D Turner (JD)

9Barrow Neurological Institute, Phoenix, Arizona.

Jack J Knightly (JJ)

10Altair Health Spine and Wellness, Morristown, New Jersey.

Kai-Ming Fu (KM)

11Department of Neurological Surgery, Weill Cornell Medicine, New York, New York.

Kevin T Foley (KT)

12Department of Neurosurgery, University of Tennessee, Memphis, Tennessee.

Luis Tumialan (L)

9Barrow Neurological Institute, Phoenix, Arizona.

Mark Shaffrey (M)

1Department of Neurosurgery, University of Virginia, Charlottesville, Virginia.

Mohamad Bydon (M)

3Department of Neurosurgery, Mayo Clinic, Rochester, Minnesota.

Praveen V Mummaneni (PV)

5Department of Neurosurgery, University of California, San Francisco, San Francisco, California.

Paul Park (P)

13Department of Neurosurgery, University of Michigan, Ann Arbor, Michigan.

Scott Meyer (S)

10Altair Health Spine and Wellness, Morristown, New Jersey.

Anthony L Asher (AL)

7Carolina Neurosurgery and Spine Associates, Charlotte, North Carolina.

Oren N Gottfried (ON)

14Department of Neurological Surgery, Duke University Medical Center, Durham, North Carolina; and.

Khoi D Than (KD)

14Department of Neurological Surgery, Duke University Medical Center, Durham, North Carolina; and.

Michael Y Wang (MY)

15Department of Neurological Surgery, University of Miami Miller School of Medicine, Miami, Florida.

Avery L Buchholz (AL)

1Department of Neurosurgery, University of Virginia, Charlottesville, Virginia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH